Gerry Coghlan

Consultant Cardiologist

Research area

Pulmonary hypertension and interventional cardiology.

Research programme

• Immune regulation

Research summary

As the National centre for connective tissue disease associated pulmonary hypertension, the main focus of our research is pulmonary hypertension in the setting of autoimmune diseases.

We recruit for many clinical trials, undertake registry studies as well as translational research.

Our ambition is to ensure that as many patients as possible can benefit from participation in trials and to continually further our understanding of this complex group of patients.

Patient involvement

In addition to working with our patients to ensure inclusion in trials, we have a patient panel that works with patients educating them in the advantages and disadvantages of ambulatory therapy and to review protocols for patient impact.

We perform an annual audit of patient satisfaction with the service provided.

Publications

Selected publications

• Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol. 2018. 14(9):511-527.
• Dawson A, Reddecliffe S, Coghlan C, Schreiber BE, Coghlan JG. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. Eur J Cardiovasc Nurs. 2018. 17(7):612-618.
• Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, Marra AM, Benjamin N, Fischer C, Grünig E. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J. 2018. 51(4). pii: 1701197.
• Coghlan JG. Balloon pulmonary angioplasty: does it have a role in CTED? Pulm Circ. 2018. 8(1):2045893218754887.
• Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018. 18(1):37-47.
• Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis. 2018. 77(1):128-132.
• Schwaiger JP, Knight DS, Kaier T, Gallimore A, Denton CP, Schreiber BE, Handler C, Coghlan JG. Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension. Echocardiography. 2017. 34(6):817-824.
• Connolly MJ, Abdullah S, Ridout DA, Schreiber BE, Haddock JA, Coghlan JG. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. Rheumatology (Oxford). 2017. 56(12):2197-2203.
• Schwaiger JP, Loder CD, Dobarro D, Kaier T, Reddecliffe S, Schreiber BE, Handler C, Denton CP, Coghlan JG. Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis. Sci Rep. 2017. 7:43304.
• Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017. 76(7):1219-1227.